Job Cuts As Nordic Nanovector Extends Cash Runway
Biotech’s Priority Is Pivotal Betalutin Study But COVID-19 Uncertainty Remains
Shrinking cash and COVID-19 uncertainty have prompted Nordic Nanovector to slash costs and focus purely on its lead asset’s pivotal trial in third-line follicular lymphoma.
